Humans have spent thousands of years experimenting with weight loss aids. While Ozempic and Wegovy may be generating ...

While employers aren’t yet reimbursing weight loss drugs en masse, significantly reduced net costs could affect their future ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The Pharma world is seeing a big opportunity in GLP-1s – the new innovative fast emerging drugs for diabetes & obesity. Kiran ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced stages of clinical development in China. Phase 2 data suggest ...

The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly's (NYSE: LLY) Zepbound delivering ...

Most current drugs for obesity and diabetes, like liraglutide, target a hormone receptor known as GLP-1. These medications ...

Wall Street on Friday posted a strong monthly advance, though stocks finished mixed on the final day of May after U.S. President Donald Trump said China had "totally violated" a trade truce.  The S&P ...

A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...

Scientists found brain cells behind semaglutide’s weight-loss power—and they don’t cause the nasty side effects.

The cultural acceptance of the 'dad bod' masks serious health risks for men, as visceral fat leads to diseases and increased mortality, requiring urgent attention.

The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...